The Finnish Cardiovascular Study (FINCAVAS): Characterising patients with high risk of cardiovascular morbidity and mortality

被引：51

作者：

Nieminen T. ^{[1
]}

Lehtinen R. ^{[2
,3
]}

Viik J. ^{[4
]}

Lehtimäki T. ^{[5
,6
]}

Niemelä K. ^{[7
]}

Nikus K. ^{[7
]}

Niemi M. ^{[7
]}

Kallio J. ^{[4
]}

Kööbi T. ^{[2
]}

Turjanmaa V. ^{[2
]}

Kähönen M. ^{[2
]}

机构：

[1] Department of Pharmacological Sciences, Medical School, University of Tampere, Tampere

[2] Department of Clinical Physiology, Tampere University Hospital and Medical School, Tampere

[3] Tampere Polytechnic-University of Applied Sciences, Tampere

[4] Ragnar Granit Institute, Tampere University of Technology, Tampere

[5] Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Tampere University Hospital, Tampere

[6] Centre for Laboratory Medicine, Medical School, University of Tampere, Tampere

[7] Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere

来源：

BMC Cardiovascular Disorders | / 6卷 / 1期

关键词：

Coronary Heart Disease; Exercise Test; Left Anterior Descend; Heart Rate Recovery; Exercise Stress Test;

D O I：

10.1186/1471-2261-6-9

中图分类号：

学科分类号：

摘要：

Background: The purpose of the Finnish Cardiovascular Study (FINCAVAS) is to construct a risk profile - using genetic, haemodynamic and electrocardiographic (ECG) markers - of individuals at high risk of cardiovascular diseases, events and deaths. Methods and design: All patients scheduled for an exercise stress test at Tampere University Hospital and willing to participate have been and will be recruited between October 2001 and December 2007. The final number of participants is estimated to reach 5,000. Technically successful data on exercise tests using a bicycle ergometer have been collected of 2,212 patients (1,400 men and 812 women) by the end of 2004. In addition to repeated measurement of heart rate and blood pressure, digital high-resolution ECG at 500 Hz is recorded continuously during the entire exercise test, including the resting and recovery phases. About 20% of the patients are examined with coronary angiography. Genetic variations known or suspected to alter cardiovascular function or pathophysiology are analysed to elucidate the effects and interactions of these candidate genes, exercise and commonly used cardiovascular medications. Discussion: FINCAVAS compiles an extensive set of data on patient history, genetic variation, cardiovascular parameters, ECG markers as well as follow-up data on clinical events, hospitalisations and deaths. The data enables the development of new diagnostic and prognostic tools as well as assessments of the importance of existing markers. © 2006 Nieminen et al., licensee BioMed Central Ltd.

引用

页数：8

共 46 条

[11]

Anantharam A., Markowitz S.M., Abbott G.W., Pharmacogenetic considerations in diseases of cardiac ion channels, J Pharmacol Exp Ther, 307, pp. 831-838, (2003)

[12]

Wilde A.A., Bezzina C.P., Genetics of cardiac arrhythmias, Heart, 91, pp. 1352-1358, (2005)

[13]

Small K.M., McGraw D.W., Liggett S.B., Pharmacology and physiology of human adrenergic receptor polymorphisms, Annu Rev Pharmacol Toxicol, 43, pp. 381-411, (2003)

[14]

Liggett S.B., Polymorphisms of adrenergic receptors: Variations on a theme, Assay Drug Dev Technol, 1, pp. 317-326, (2003)

[15]

Imamura A., Okumura K., Matsui H., Mizuno T., Ogawa Y., Imai H., Numaguichi Y., Sakai K., Murohara T., Endothelial nitric oxide synthase and methylenetetrahydrofolate reductase gene polymorphisms are associated with endothelial dysfunction in young, healthy men, Can J Cardiol, 20, pp. 1229-1234, (2004)

[16]

Puddu P., Cravero E., Puddu G.M., Muscari A., Genes and atherosclerosis: At the origin of the predisposition, Int J Clin Pract, 59, pp. 462-472, (2005)

[17]

Tobin M.D., Raleigh S.M., Newhouse S., Braund P., Bodycote C., Ogleby J., Cross D., Gracey J., Hayes S., Smith T., Ridge C., Caulfield M., Sheehan N.A., Munroe P.B., Burton P.R., Samani N.J., Association of WNKI Gene Polymorphisms and Haplotypes With Ambulatory Blood Pressure in the General Population, Circulation, (2005)

[18]

Bengtsson K., Melander O., Orho-Melander M., Lindblad U., Ranstam J., Rastam L., Groop L., Polymorphism in the beta(1)-adrenergic receptor gene and hypertension, Circulation, 104, pp. 187-190, (2001)

[19]

Poller W., Kuhl U., Tschoepe C., Pauschinger M., Fechner H., Schultheiss H.P., Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy, J Mol Med, 83, pp. 579-586, (2005)

[20]

Bouchard C., Rankinen T., Individual differences in response to regular physical activity, Med Sci Sports Exerc, 33, pp. 446-453, (2001)

← 1 2 3 4 5 →